SG11201805237TA - Novel 1,2,3 triazole-thiazole compounds, process for preparation and use thereof - Google Patents
Novel 1,2,3 triazole-thiazole compounds, process for preparation and use thereofInfo
- Publication number
- SG11201805237TA SG11201805237TA SG11201805237TA SG11201805237TA SG11201805237TA SG 11201805237T A SG11201805237T A SG 11201805237TA SG 11201805237T A SG11201805237T A SG 11201805237TA SG 11201805237T A SG11201805237T A SG 11201805237TA SG 11201805237T A SG11201805237T A SG 11201805237TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- csir
- road
- new delhi
- vihar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4189DE2015 | 2015-12-21 | ||
| PCT/IN2016/050449 WO2017109793A1 (en) | 2015-12-21 | 2016-12-20 | Novel 1,2,3 triazole-thiazole compounds, process for preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805237TA true SG11201805237TA (en) | 2018-07-30 |
Family
ID=58191512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805237TA SG11201805237TA (en) | 2015-12-21 | 2016-12-20 | Novel 1,2,3 triazole-thiazole compounds, process for preparation and use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10246449B2 (ja) |
| EP (1) | EP3394054B1 (ja) |
| JP (1) | JP6586528B2 (ja) |
| BR (1) | BR112018012701A2 (ja) |
| SG (1) | SG11201805237TA (ja) |
| WO (1) | WO2017109793A1 (ja) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| US7259262B2 (en) * | 2003-10-24 | 2007-08-21 | Hoffmann-La Roche Inc. | Arylazole derivatives, their manufacture and use as pharmaceutical agents |
| KR20080047591A (ko) * | 2005-09-07 | 2008-05-29 | 플렉시콘, 인코퍼레이티드 | Ｐｐａｒ 조절인자로서 사용하기 위한 1,3-이치환된 인돌유도체 |
| WO2007087427A2 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
| EP2464635B1 (en) | 2009-08-11 | 2015-09-16 | The Scripps Research Institute | Copper catalyzed cycloaddition of organic azides and 1-haloalkynes |
| US8377970B2 (en) * | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| EP3092236B1 (en) * | 2014-01-06 | 2020-08-26 | Rhizen Pharmaceuticals S.A. | Novel glutaminase inhibitors |
-
2016
- 2016-12-20 WO PCT/IN2016/050449 patent/WO2017109793A1/en active Application Filing
- 2016-12-20 SG SG11201805237TA patent/SG11201805237TA/en unknown
- 2016-12-20 EP EP16840334.3A patent/EP3394054B1/en not_active Not-in-force
- 2016-12-20 BR BR112018012701A patent/BR112018012701A2/pt not_active Application Discontinuation
- 2016-12-20 JP JP2018532402A patent/JP6586528B2/ja not_active Expired - Fee Related
- 2016-12-20 US US16/064,415 patent/US10246449B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US10246449B2 (en) | 2019-04-02 |
| BR112018012701A2 (pt) | 2018-12-04 |
| WO2017109793A1 (en) | 2017-06-29 |
| JP2019501168A (ja) | 2019-01-17 |
| EP3394054A1 (en) | 2018-10-31 |
| EP3394054B1 (en) | 2019-11-06 |
| JP6586528B2 (ja) | 2019-10-02 |
| US20180370962A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201809132RA (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib |